US 11,752,111 B2
Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
Geoffrey Guy, Cambridge (GB); Stephen Wright, Cambridge (GB); James Brodie, Cambridge (GB); Marie Woolley-Roberts, Cambridge (GB); Rafael Maldonado, Barcelona (ES); Daniela Parolaro, Varese (IT); Livio Luongo, Naples (IT); and Joanna Neill, Manchester (GB)
Assigned to GW RESEARCH LIMITED, Cambridge (GB)
Appl. No. 16/92,374
Filed by GW Research Limited, Cambridge (GB)
PCT Filed Apr. 11, 2017, PCT No. PCT/GB2017/051007
§ 371(c)(1), (2) Date Oct. 9, 2018,
PCT Pub. No. WO2017/178807, PCT Pub. Date Oct. 19, 2017.
Claims priority of application No. 1606098 (GB), filed on Apr. 11, 2016.
Prior Publication US 2019/0160023 A1, May 30, 2019
Int. Cl. A61K 31/05 (2006.01); A61K 36/185 (2006.01); A61K 45/06 (2006.01); A61K 31/352 (2006.01); A61P 25/28 (2006.01); A61P 25/18 (2006.01); A61K 36/00 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 31/352 (2013.01); A61K 36/185 (2013.01); A61K 45/06 (2013.01); A61P 25/18 (2018.01); A61P 25/28 (2018.01)] 18 Claims
 
1. A method of treating one or more symptoms or disease characteristics associated with autistic spectrum disorder (ASD) or ASD-associated disorders, as defined by DSM-IV, in a subject in need thereof, the method comprising administering cannabidivarin to the subject, wherein the one or more symptoms or disease characteristics are one or more of: (i) qualitative impairment in social interaction; (ii) qualitative impairment in communication; and (iii) restricted repetitive and stereotyped patterns of behaviour interest and activities.